{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T18:38:00Z","timestamp":1789324680088,"version":"build-2803163510"},"reference-count":179,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["NIHR135592"],"award-info":[{"award-number":["NIHR135592"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\"><jats:title>Background<\/jats:title>\n<jats:p>To limit the use of antimicrobials without disincentivising the development of novel antimicrobials, there is interest in establishing innovative models that fund antimicrobials based on an evaluation of their value as opposed to the volumes used. The aim of this project was to evaluate the population-level health benefit of ceftazidime-avibactam in the NHS in England, for the treatment of severe aerobic Gram-negative bacterial infections when used within its licensed indications. The results were used to inform National Institute for Health and Care Excellence guidance in support of commercial discussions regarding contract value between the manufacturer and NHS England.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-2\"><jats:title>Methods<\/jats:title>\n<jats:p>The health benefit of ceftazidime-avibactam was first derived for a series of high-value clinical scenarios. These represented uses that were expected to have a significant impact on patients\u2019 mortality risks and health-related quality of life. Patient-level costs and health-related quality of life of ceftazidime-avibactam under various usage scenarios compared with alternative management strategies in the high-value clinical scenarios were quantified using decision modelling. Results were reported as incremental net health effects expressed in quality-adjusted life-years, which were scaled to 20-year population in quality-adjusted life-years using infection number forecasts based on data from Public Health England. The outcomes estimated for the high-value clinical scenarios were extrapolated to other expected uses for ceftazidime-avibactam.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-3\"><jats:title>Results<\/jats:title>\n<jats:p>The clinical effectiveness of ceftazidime-avibactam relative to its comparators was estimated by synthesising evidence on susceptibility of the pathogens of interest to the antimicrobials in a network meta-analysis. In the base case, ceftazidime-avibactam was associated with a statistically significantly higher susceptibility relative to colistin (odds ratio 7.24, 95% credible interval 2.58 to 20.94). The remainder of the treatments were associated with lower susceptibility than colistin (odds ratio &lt; 1). The results were sensitive to the definition of resistance and the studies included in the analysis.<\/jats:p>\n<jats:p>In the base case, patient-level benefit of ceftazidime-avibactam was between 0.08 and 0.16 quality-adjusted life-years, depending on the site of infection and the usage scenario. There was a high degree of uncertainty surrounding the benefits of ceftazidime-avibactam across all subgroups, and the results were sensitive to assumptions in the meta-analysis used to estimate susceptibility. There was substantial uncertainty in the number of infections that are suitable for treatment with ceftazidime-avibactam, so population-level results are presented for a range of scenarios for the current infection numbers, the expected increases in infections over time, and rates of emergence of resistance. The population-level benefit varied substantially across the scenarios, from 531 to 2342 quality-adjusted life-years over 20 years.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-4\"><jats:title>Conclusion<\/jats:title>\n<jats:p>This work has provided quantitative estimates of the value of ceftazidime-avibactam within its areas of expected usage within the NHS.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-5\"><jats:title>Limitations<\/jats:title>\n<jats:p>Given existing evidence, the estimates of the value of ceftazidime-avibactam are highly uncertain.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-6\"><jats:title>Future work<\/jats:title>\n<jats:p>Future evaluations of antimicrobials would benefit from improvements to NHS data linkages, research to support appropriate synthesis of susceptibility studies, and application of routine data and decision modelling to assess enablement value.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-7\"><jats:title>Study registration<\/jats:title>\n<jats:p>No registration of this study was undertaken.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-8\"><jats:title>Funding<\/jats:title>\n<jats:p>This award was funded by the National Institute for Health and Care Research (NIHR) Policy Research Programme (NIHR award ref: NIHR135592), conducted through the Policy Research Unit in Economic Methods of Evaluation in Health and Social Care Interventions, PR-PRU-1217-20401, and is published in full in <jats:italic>Health Technology Assessment<\/jats:italic>; Vol. 28, No. 73. See the NIHR Funding and Awards website for further award information.<\/jats:p>\n<\/jats:sec>","DOI":"10.3310\/yapl9347","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T07:52:26Z","timestamp":1730533946000},"page":"1-230","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9318-9206","authenticated-orcid":true,"given":"Sue","family":"Harnan","sequence":"first","affiliation":[{"name":"Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7730-668X","authenticated-orcid":true,"given":"Ben","family":"Kearns","sequence":"additional","affiliation":[{"name":"Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1604-1758","authenticated-orcid":true,"given":"Alison","family":"Scope","sequence":"additional","affiliation":[{"name":"Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1052-488X","authenticated-orcid":true,"given":"Laetitia","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9311-1409","authenticated-orcid":true,"given":"Dina","family":"Jankovic","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3326-9842","authenticated-orcid":true,"given":"Jean","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5961-9348","authenticated-orcid":true,"given":"Tushar","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0908-5595","authenticated-orcid":true,"given":"Harry","family":"Hill","sequence":"additional","affiliation":[{"name":"Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4719-117X","authenticated-orcid":true,"given":"Chu Chang","family":"Ku","sequence":"additional","affiliation":[{"name":"Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3568-7124","authenticated-orcid":true,"given":"Shijie","family":"Ren","sequence":"additional","affiliation":[{"name":"Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7759-4084","authenticated-orcid":true,"given":"Claire","family":"Rothery","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7921-9109","authenticated-orcid":true,"given":"Laura","family":"Bojke","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3746-9913","authenticated-orcid":true,"given":"Mark","family":"Sculpher","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7669-9415","authenticated-orcid":true,"given":"Beth","family":"Woods","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2024,10]]},"reference":[{"key":"key2024110213133500_ref1-bib1","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1093\/jac\/dky027","article-title":"Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy\/Healthcare Infection Society\/British Infection Association Joint working party","volume":"73","author":"Hawkey","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"key2024110213133500_ref2-bib2","volume-title":"Virulence Mechanisms of Bacterial Pathogens","author":"Munita","year":"2016"},{"key":"key2024110213133500_ref3-bib3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jhin.2015.01.008","article-title":"Multidrug-resistant Gram-negative bacteria: a product of globalization","volume":"89","author":"Hawkey","year":"2015","journal-title":"J Hosp Infect"},{"key":"key2024110213133500_ref4-bib4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jac\/dkl558","article-title":"Don\u2019t wear me out: the public\u2019s knowledge of and attitudes to antibiotic use","volume":"59","author":"McNulty","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"key2024110213133500_ref6-bib6","doi-asserted-by":"crossref","first-page":"dlaa075","DOI":"10.1093\/jacamr\/dlaa075","article-title":"Treating infections caused by carbapenemase-producing Enterobacterales (CPE): a pragmatic approach to antimicrobial stewardship on behalf of the UKCPA Pharmacy Infection Network (PIN)","volume":"2","author":"Hughes","year":"2020","journal-title":"JAC-Antimicrobial Resistance"},{"key":"key2024110213133500_ref9-bib9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2147\/IDR.S246174","article-title":"Therapeutic options for metallo-\u03b2-lactamase-producing Enterobacterales","volume":"14","author":"Tan","year":"2021","journal-title":"Infect Drug Resist"},{"key":"key2024110213133500_ref10-bib10","volume-title":"Zavicefta 2\u2009g\/0.5 g Powder for Concentrate for Solution for Infusion \u2013 Summary of Product Characteristics (SPC) \u2013 (eMC)","author":"Medicines.org.uk","year":"2021"},{"key":"key2024110213133500_ref11-bib11","volume-title":"European Public Assessment Reports \u2013 Zavicefta \u2013 EMEA\/H\/C\/004027 \u2013 II\/0015","author":"European Medicines Agency","year":"2021"},{"key":"key2024110213133500_ref12-bib12","volume-title":"Framework for Value Assessment of New Pharmaceuticals: Implications of alternative funding arrangements for NICE Appraisal","author":"Rothery","year":"2018"},{"key":"key2024110213133500_ref13-bib13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciy576","article-title":"Ceftazidime\/avibactam, meropenem\/vaborbactam, or both? Clinical and formulary considerations","volume":"68","author":"Pogue","year":"2019","journal-title":"Clin Infect Dis"},{"key":"key2024110213133500_ref14-bib14","first-page":"1","article-title":"Molecular surveillance of carbapenemase-producing Pseudomonas aeruginosa at three medical centres in Cologne, Germany","volume":"8","author":"Sch\u00e4fer","year":"2019","journal-title":"Antimicrob Resist Infect Contr"},{"key":"key2024110213133500_ref15-bib15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/jpids\/piz002","article-title":"Defining the role of novel \u03b2-lactam agents that target carbapenem-resistant Gram-negative organisms","volume":"8","author":"Tamma","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"key":"key2024110213133500_ref18-bib18","volume-title":"Paterson Setting and Revising Antibacterial Susceptibility Breakpoints","author":"Turnidge"},{"key":"key2024110213133500_ref19-bib19","volume-title":"Setting Breakpoints for New Antimicrobial Agents, EUCAST SOP 1.3","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2019"},{"key":"key2024110213133500_ref20-bib20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1332\/174426414X14199471271588","article-title":"Pruning and prioritising: a case study of a pragmatic method for managing a rapid systematic review with limited resources","volume":"11","author":"Harnan","year":"2015","journal-title":"Evidence & Policy"},{"key":"key2024110213133500_ref21-bib21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ebiom.2016.07.004","article-title":"Building the evidence base of blood-based biomarkers for early detection of cancer: a rapid systematic mapping review","volume":"10","author":"Uttley","year":"2016","journal-title":"EBioMed"},{"key":"key2024110213133500_ref22-bib22","volume-title":"NICE DSU Technical Support Document 13: Identifying and Reviewing Evidence to Inform the Conceptualisation and Population of Cost-Effectiveness Models","author":"Kaltenthaler","year":"2011"},{"key":"key2024110213133500_ref23-bib23","volume-title":"Antimicrobial Testing Leadership and Surveillance (ATLAS)","author":"Pfizer Inc."},{"key":"key2024110213133500_ref24-bib24","volume-title":"SENTRY Microbiology Visualization Platform (MVP)","author":"Element"},{"key":"key2024110213133500_ref25-bib25","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jclinepi.2011.11.014","article-title":"Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement","volume":"65","author":"Hoy","year":"2012","journal-title":"J Clin Epidemiol"},{"key":"key2024110213133500_ref26-bib26","volume-title":"JBI Manual for Evidence Synthesis","author":"Munn","year":"2020"},{"key":"key2024110213133500_ref27-bib27","first-page":"175","article-title":"ROBINS-1: a tool for asssessing risk of bias in non-randomised studies of interventions","volume":"40","author":"Hinneburg","year":"2017","journal-title":"Med Monatsschr Pharm"},{"key":"key2024110213133500_ref28-bib28","first-page":"1","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"key2024110213133500_ref29-bib29","volume-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses","author":"Peterson","year":"2011"},{"key":"key2024110213133500_ref32-bib32","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/AAC.00756-10","article-title":"Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae","volume":"55","author":"Livermore","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key2024110213133500_ref33-bib33","author":"Deshpande","year":"2021"},{"key":"key2024110213133500_ref34-bib34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1128\/AAC.00592-18","article-title":"In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against OXA-48-carrying Enterobacteriaceae isolated as part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015","volume":"62","author":"Kazmierczak","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"key2024110213133500_ref35-bib35","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/jac\/dkab043","article-title":"Activity of imipenem\/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales","volume":"76","author":"Vazquez-Ucha","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"key2024110213133500_ref36-bib36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ijantimicag.2018.01.011","article-title":"Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain","volume":"51","author":"Garcia-Castillo","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"key2024110213133500_ref37-bib37","first-page":"dlaa060","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe","volume":"2","author":"Longshaw","year":"2020","journal-title":"JAC: Antimicrob Resist"},{"key":"key2024110213133500_ref38-bib38","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/1120009X.2020.1761172","article-title":"Evaluation of the synergy of ceftazidime\/avibactam in combination with colistin, doripenem, levofloxacin, tigecycline, and tobramycin against OXA-48 producing Enterobacterales","volume":"32","author":"Mataraci Kara","year":"2020","journal-title":"J Chemother"},{"key":"key2024110213133500_ref39-bib39","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fcimb.2020.00314","article-title":"Dissemination of carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant Enterobacteriaceae isolated from adult and children patients in China","volume":"10","author":"Han","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"key2024110213133500_ref40-bib40","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1002\/sim.4288","article-title":"Methods to elicit experts\u2019 beliefs over uncertain quantities: application to a cost effectiveness transition model of negative pressure wound therapy for severe pressure ulceration","volume":"30","author":"Soares","year":"2011","journal-title":"Stat Med"},{"key":"key2024110213133500_ref41-bib41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","article-title":"In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-beta-lactamase-producing isolates (SIDERO-WT-2014 Study)","volume":"53","author":"Kazmierczak","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"key2024110213133500_ref42-bib42","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1089\/mdr.2018.0439","article-title":"Assessment of the in vitro activities of ceftolozane\/tazobactam and ceftazidime\/avibactam in a collection of beta-lactam-resistant Enterobacteriaceae and Pseudomonas aeruginosa clinical isolates at Montpellier University Hospital, France","volume":"25","author":"Viala","year":"2019","journal-title":"Microb Drug Resist"},{"key":"key2024110213133500_ref43-bib43","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ijantimicag.2018.11.015","article-title":"Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam","volume":"53","author":"De la Calle","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"key2024110213133500_ref44-bib44","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s10096-019-03517-y","article-title":"In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015\u20132016","volume":"38","author":"Galani","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key2024110213133500_ref45-bib45","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijantimicag.2018.02.017","article-title":"Ceftazidime\/avibactam susceptibility by three different susceptibility testing methods in carbapenemase-producing Gram-negative bacteria from Australia","volume":"52","author":"Sherry","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"key2024110213133500_ref46-bib46","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1093\/jac\/dkaa353","article-title":"Activity of cefepime\/zidebactam against MDR Escherichia coli isolates harbouring a novel mechanism of resistance based on four-amino-acid inserts in PBP3","volume":"75","author":"Bhagwat","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"key2024110213133500_ref47-bib47","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key2024110213133500_ref48-bib48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"key2024110213133500_ref49-bib49","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"key2024110213133500_ref50-bib50","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a Phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key2024110213133500_ref51-bib51","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1186\/s12879-019-4409-1","article-title":"Efficacy of ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"19","author":"Alraddadi","year":"2019","journal-title":"BMC Infect Dis"},{"key":"key2024110213133500_ref52-bib52","doi-asserted-by":"crossref","first-page":"e0195757","DOI":"10.1371\/journal.pone.0195757","article-title":"Carbapenem-resistant Gram-negative pathogens in a German university medical center: prevalence, clinical implications and the role of novel beta-lactam\/beta-lactamase inhibitor combinations","volume":"13","author":"Katchanov","year":"2018","journal-title":"PLOS ONE"},{"key":"key2024110213133500_ref53-bib53","doi-asserted-by":"crossref","first-page":"100033","DOI":"10.1016\/j.infpip.2019.100033","article-title":"An outbreak of two strains of OXA-48 producing Klebsiella pneumoniae in a teaching hospital","volume":"2","author":"Lim","year":"2020","journal-title":"Infect Prev Pract"},{"key":"key2024110213133500_ref54-bib54","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1093\/jac\/dky295","article-title":"Effectiveness of ceftazidime\/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae","volume":"73","author":"Sousa","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"key2024110213133500_ref55-bib55","doi-asserted-by":"crossref","first-page":"02","DOI":"10.1128\/AAC.01964-16","article-title":"Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms","volume":"61","author":"Temkin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key2024110213133500_ref56-bib56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/14787210.2020.1810568","article-title":"Experience of ceftazidime\/avibactam in a UK tertiary cardiopulmonary specialist center","volume":"19","author":"Nwankwo","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"key2024110213133500_ref58-bib58","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jac\/dkaa503","article-title":"Ceftazidime\/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study","volume":"76","author":"Karaiskos","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"key2024110213133500_ref59-bib59","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1128\/AAC.03042-15","article-title":"In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM Global Surveillance Study (2012 to 2014)","volume":"60","author":"de Jonge","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key2024110213133500_ref60-bib60","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s10096-017-3063-z","article-title":"Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens","volume":"36","author":"Dobias","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key2024110213133500_ref61-bib61","doi-asserted-by":"crossref","first-page":"1700775","DOI":"10.2807\/1560-7917.ES.2018.23.30.1700775","article-title":"Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016","volume":"23","author":"Galani","year":"2018","journal-title":"Euro Surveill"},{"key":"key2024110213133500_ref62-bib62","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1128\/AAC.02569-17","article-title":"In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Asia-Pacific countries: results from the INFORM Global Surveillance Program, 2012 to 2015","volume":"62","author":"Karlowsky","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"key2024110213133500_ref63-bib63","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1128\/AAC.01814-18","article-title":"In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Latin American countries: results from the INFORM Global Surveillance Program, 2012 to 2015","volume":"63","author":"Karlowsky","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"key2024110213133500_ref64-bib64","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/jac\/dkx438","article-title":"Activity of ceftazidime\/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015\u201316","volume":"73","author":"Livermore","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"key2024110213133500_ref65-bib65","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/jac\/dkw593","article-title":"In vitro activity of cefepime\/zidebactam (WCK 5222) against Gram-negative bacteria","volume":"72","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key2024110213133500_ref66-bib66","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1089\/mdr.2019.0090","article-title":"Changing characteristics and in vitro susceptibility to ceftazidime\/avibactam of bloodstream extensively drug-resistant Klebsiella pneumoniae from a Greek intensive care unit","volume":"26","author":"Mavroidi","year":"2020","journal-title":"Microb Drug Resist"},{"key":"key2024110213133500_ref67-bib67","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/jac\/dkab067","article-title":"Activity of cefepime\/zidebactam (WCK 5222) against \u2018problem\u2019 antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory","volume":"76","author":"Mushtaq","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"key2024110213133500_ref68-bib68","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/jac\/dkaa117","article-title":"Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia","volume":"75","author":"Delgado-Valverde","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"key2024110213133500_ref70-bib70","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/jac\/dkv287","article-title":"Antimicrobial susceptibility testing breakpoints and methods from BSAC to EUCAST","volume":"71","author":"Brown","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key2024110213133500_ref71-bib71","volume-title":"NICE DSU Technical Support Document 3: Heterogeneity: Subgroups, Meta-Regression, Bias and Bias-Adjustment","author":"Dias","year":"2011"},{"key":"key2024110213133500_ref72-bib72","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1008929526011","article-title":"WinBUGS \u2013 a Bayesian modelling framework: concepts, structure, and extensibility","volume":"10","author":"Lunn","year":"2000","journal-title":"Stat Comput"},{"key":"key2024110213133500_ref73-bib73","volume-title":"NICE Technical Support Document 2. A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials","author":"Dias","year":"2011"},{"key":"key2024110213133500_ref74-bib74","volume-title":"NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials","author":"Dias","year":"2014"},{"key":"key2024110213133500_ref75-bib75","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"General methods for monitoring convergence of iterative simulation","volume":"7","author":"Brooks","year":"2021","journal-title":"J Comput Graph Statist"},{"key":"key2024110213133500_ref76-bib76","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/1467-9868.00353","article-title":"Bayesian measures of model complexity and fit","volume":"64","author":"Spiegelhalter","year":"2002","journal-title":"J R Statist Soc: Ser B (Statist Methodol)"},{"key":"key2024110213133500_ref77-bib77","volume-title":"NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials","author":"Dias","year":"2011"},{"key":"key2024110213133500_ref78-bib78","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","article-title":"In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-\u03b2-lactamase-producing isolates (SIDERO-WT-2014 Study)","volume":"53","author":"Kazmierczak","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"key2024110213133500_ref79-bib79","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1093\/jac\/dkaa353","article-title":"Activity of cefepime\/zidebactam against MDR Escherichia coli isolates harbouring a novel mechanism of resistance based on four-amino-acid inserts in PBP3","volume":"75","author":"Bhagwat","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"key2024110213133500_ref80-bib80","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fcimb.2020.00314","article-title":"Dissemination of carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant Enterobacteriaceae isolated from adult and children patients in China","volume":"10","author":"Han","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"key2024110213133500_ref81-bib81","first-page":"e00797","article-title":"Activity of cefiderocol, ceftazidime-avibactam, and eravacycline against carbapenem-resistant Escherichia coli isolates from the United States and international sites in relation to clonal background, resistance genes, coresistance, and region","volume":"64","author":"Johnston","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"key2024110213133500_ref82-bib82","volume-title":"Cefiderocol (Fetcroja\u00ae) for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options","author":"EUnetHTA PTJA11. Authoring Team","year":"2020"},{"key":"key2024110213133500_ref83-bib83","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key2024110213133500_ref84-bib84","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"key2024110213133500_ref85-bib85","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","article-title":"Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients","volume":"59","author":"Caston","year":"2017","journal-title":"Int J Infect Dis"},{"key":"key2024110213133500_ref86-bib86","doi-asserted-by":"crossref","first-page":"08","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key2024110213133500_ref87-bib87","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin Infect Dis"},{"key":"key2024110213133500_ref88-bib88","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key2024110213133500_ref89-bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta25370","article-title":"Developing a reference protocol for structured expert elicitation in health-care decision-making: a mixed-methods study","volume":"25","author":"Bojke","year":"2021","journal-title":"Health Technol Assess"},{"key":"key2024110213133500_ref91-bib91","doi-asserted-by":"crossref","DOI":"10.1002\/0470033312","volume-title":"Uncertain Judgements: Eliciting Experts\u2019 Probabilities","author":"O\u2019Hagan","year":"2006"},{"key":"key2024110213133500_ref92-bib92","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.clinthera.2020.03.014","article-title":"Cost-effectiveness comparison of ceftazidime\/avibactam versus meropenem in the empirical treatment of hospital-acquired pneumonia, including ventilator-associated pneumonia, in Italy","volume":"42","author":"Tichy","year":"2020","journal-title":"Clin Ther"},{"key":"key2024110213133500_ref93-bib93","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ijantimicag.2019.06.008","article-title":"Cost-effectiveness analysis of ceftazidime\/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections","volume":"54","author":"Kongnakorn","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"key2024110213133500_ref94-bib94","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1128\/AAC.00897-19","article-title":"Cost-effectiveness of ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae bacteremia and pneumonia","volume":"63","author":"Simon","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"key2024110213133500_ref95-bib95","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ijantimicag.2019.07.003","article-title":"Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs meropenem for Gram-negative infections: a systematic review, meta-analysis, and cost-effectiveness analysis","volume":"54","author":"Nguyen","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"key2024110213133500_ref96-bib96","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jmii.2019.04.003","article-title":"Comparing ceftolozane\/tazobactam versus piperacillin\/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: a cost-utility model focusing on Gram-negative bacteria","volume":"52","author":"Chen","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"key2024110213133500_ref97-bib97","doi-asserted-by":"crossref","first-page":"e0214222","DOI":"10.1371\/journal.pone.0214222","article-title":"The cost impact of PCT-guided antibiotic stewardship versus usual care for hospitalised patients with suspected sepsis or lower respiratory tract infections in the US: a health economic model analysis","volume":"14","author":"Mewes","year":"2019","journal-title":"PLOS ONE"},{"key":"key2024110213133500_ref98-bib98","article-title":"Evaluating the cost-effectiveness of decolonization for prevention of MRSA infections using a dynamic transmission model. Antimicrobial Resistance and Infection Control Conference: 5th International Conference on Prevention and Infection Control","volume":"8","author":"Nelson","year":"2019","journal-title":"ICPIC"},{"key":"key2024110213133500_ref99-bib99","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40273-020-00906-6","article-title":"Estimating the value of new antimicrobials in the context of antimicrobial resistance: development and application of a dynamic disease transmission model","volume":"38","author":"Gordon","year":"2020","journal-title":"PharmacoEcon"},{"key":"key2024110213133500_ref100-bib100","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jhin.2020.09.012","article-title":"Review of health economic models exploring and evaluating treatment and management of hospital-acquired pneumonia and ventilator-associated pneumonia","volume":"106","author":"Wagner","year":"2020","journal-title":"J Hosp Infect"},{"key":"key2024110213133500_ref101-bib101","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10198-011-0296-0","article-title":"Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin\/tazobactam","volume":"13","author":"Edwards","year":"2012","journal-title":"Eur J Health Econ"},{"key":"key2024110213133500_ref102-bib102","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1179\/joc.2005.17.2.203","article-title":"Cost-effectiveness analysis of the treatment of ventilator-associated pneumonia with linezolid or vancomycin in Spain","volume":"17","author":"Grau","year":"2005","journal-title":"J Chemother"},{"key":"key2024110213133500_ref103-bib103","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1185\/03007990903358980","article-title":"Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation","volume":"26","author":"Kongnakorn","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"key2024110213133500_ref104-bib104","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s12879-017-2408-7","article-title":"Cost-effectiveness of ceftolozane\/tazobactam compared with piperacillin\/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections","volume":"17","author":"Kauf","year":"2017","journal-title":"BMC Infect Dis"},{"key":"key2024110213133500_ref106-bib106","volume-title":"Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions","author":"Schaffer","year":"2017"},{"key":"key2024110213133500_ref107-bib107","volume-title":"Aminoglycosides (Gentamicin, Amikacin, Tobramycin, and Neomycin): Increased Risk of Deafness in Patients with Mitochondrial Mutations. GOV.UK","year":"2021"},{"key":"key2024110213133500_ref108-bib108","volume-title":"National Institute of Health and Care Excellence, Antimicrobial Health Technology Evaluation: Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections. Company Evidence Submission, Document A.","author":"Pfizer Ltd","year":"2021"},{"key":"key2024110213133500_ref109-bib109","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s00134-013-2828-9","article-title":"Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients","volume":"39","author":"Tumbarello","year":"2013","journal-title":"Intensive Care Med"},{"key":"key2024110213133500_ref110-bib110","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/cid\/ciaa122","article-title":"Carbapenem-resistant Enterobacterales, carbapenem resistant organisms, carbapenemase-producing Enterobacterales, and carbapenemase-producing organisms: terminology past its \u201csell-by date\u201d in an era of new antibiotics and regional carbapenemase epidemiology","volume":"71","author":"Livermore","year":"2020","journal-title":"Clin Infect Dis"},{"key":"key2024110213133500_ref111-bib111","doi-asserted-by":"crossref","first-page":"105328","DOI":"10.1016\/j.phrs.2020.105328","article-title":"Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury","volume":"163","author":"Sisay","year":"2021","journal-title":"Pharmacol Res"},{"key":"key2024110213133500_ref112-bib112","doi-asserted-by":"crossref","first-page":"105889","DOI":"10.1016\/j.ijantimicag.2020.105889","article-title":"Is colistin-associated acute kidney injury clinically important in adults? A systematic review and meta-analysis","volume":"55","author":"Chien","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"key2024110213133500_ref113-bib113","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/ndt\/gfu016","article-title":"The economic impact of acute kidney injury in England","volume":"29","author":"Kerr","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"key2024110213133500_ref114-bib114","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.cmi.2020.12.009","article-title":"Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins","volume":"27","author":"Wagenlehner","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"key2024110213133500_ref115-bib115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.diagmicrobio.2018.11.008","article-title":"Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies","volume":"94","author":"Oliota","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key2024110213133500_ref116-bib116","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"key2024110213133500_ref117-bib117","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cmi.2020.10.016","article-title":"Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review","volume":"27","author":"Palacios-Baena","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"key2024110213133500_ref118-bib118","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhin.2020.12.021","article-title":"Healthcare resource use in hospitalized patients with carbapenem-resistant Gram-negative infections","volume":"110","author":"Merrick","year":"2021","journal-title":"J Hosp Infect"},{"key":"key2024110213133500_ref119-bib119","volume-title":"NICE DSU Technical Support Document 14: Survival Analysis for Economic Evaluations alongside Clinical Trials \u2013 Extrapolation with Patient-Level Data","author":"Latimer","year":"2011"},{"key":"key2024110213133500_ref120-bib120","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/ki.2011.405","article-title":"Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury","volume":"81","author":"Bucaloiu","year":"2012","journal-title":"Kidney Int"},{"key":"key2024110213133500_ref121-bib121","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/CEOR.S148405","article-title":"Pain associated with health and economic burden in France: results from recent National Health and Wellness Survey data","volume":"10","author":"Hadjiat","year":"2018","journal-title":"ClinicoEconomics Outcomes Res"},{"key":"key2024110213133500_ref122-bib122","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3111\/13696998.2012.716383","article-title":"The societal burden of pain in Germany: health-related quality-of-life, health status and direct medical costs","volume":"15","author":"Langley","year":"2012","journal-title":"J Med Econ"},{"key":"key2024110213133500_ref123-bib123","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","article-title":"Populating an economic model with health state utility values: moving toward better practice","volume":"13","author":"Ara","year":"2010","journal-title":"Value Health"},{"key":"key2024110213133500_ref124-bib124","doi-asserted-by":"crossref","first-page":"e1001307","DOI":"10.1371\/journal.pmed.1001307","article-title":"A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments","volume":"9","author":"Wyld","year":"2012","journal-title":"PLOS Med"},{"key":"key2024110213133500_ref125-bib125","doi-asserted-by":"crossref","first-page":"iii73","DOI":"10.1093\/ndt\/gfs269","article-title":"Estimating the financial cost of chronic kidney disease to the NHS in England","volume":"27","author":"Kerr","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"key2024110213133500_ref126-bib126","doi-asserted-by":"crossref","first-page":"322.e7","DOI":"10.1016\/j.jcrc.2011.09.004","article-title":"The adequacy of timely empiric antibiotic therapy for ventilator-associated pneumonia: an important determinant of outcome","volume":"27","author":"Muscedere","year":"2012","journal-title":"J Crit Care"},{"key":"key2024110213133500_ref127-bib127","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000358435","article-title":"The reimbursement and cost of acute kidney injury: a UK hospital perspective","volume":"126","author":"Kolhe","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"key2024110213133500_ref128-bib128","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12916-018-1121-8","article-title":"Quantifying where human acquisition of antibiotic resistance occurs: a mathematical modelling study","volume":"16","author":"Knight","year":"2018","journal-title":"BMC Med"},{"key":"key2024110213133500_ref129-bib129","volume-title":"Unit Costs of Health & Social Care","author":"Curtis","year":"2020"},{"key":"key2024110213133500_ref130-bib130","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13756-019-0652-x","article-title":"Cost-effectiveness analysis comparing ceftazidime\/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane\/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)","volume":"8","author":"Kongnakorn","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"key":"key2024110213133500_ref131-bib131","volume-title":"BNF: British National Formulary \u2013 NICE","author":"British National Formulary","year":"2021"},{"key":"key2024110213133500_ref132-bib132","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1007\/s00134-007-0675-2","article-title":"Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study","volume":"33","author":"Kallel","year":"2007","journal-title":"Intensive Care Med"},{"key":"key2024110213133500_ref133-bib133","volume-title":"Drugs and Pharmaceutical Electronic Market Information Tool (eMIT)","author":"Department of Health and Social Care","year":"2021"},{"key":"key2024110213133500_ref134-bib134","volume-title":"WHO Collaboration Centre for Drug Statistics Methodology","author":"World Health Organization","year":"2021"},{"key":"key2024110213133500_ref135-bib135","volume-title":"Renapime 1g Powder for Solution for Injection\/Infusion: SmPC","author":"Renascience Pharma Ltd"},{"key":"key2024110213133500_ref136-bib136","volume-title":"Antimicrobial Health Technology Evaluation: Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections: Final Scope","year":"2021"},{"key":"key2024110213133500_ref138-bib138","volume-title":"Guide to the Methods of Technology Appraisal 2013","year":"2013"},{"key":"key2024110213133500_ref139-bib139","volume-title":"New S, I and R Definitions","year":"2021"},{"key":"key2024110213133500_ref140-bib140","doi-asserted-by":"crossref","first-page":"c2096","DOI":"10.1136\/bmj.c2096","article-title":"Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis","volume":"340","author":"Costelloe","year":"2010","journal-title":"BMJ"},{"key":"key2024110213133500_ref141-bib141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-14-13","article-title":"A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance","volume":"14","author":"Bell","year":"2014","journal-title":"BMC Infect Dis"},{"key":"key2024110213133500_ref142-bib142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-018-1109-4","article-title":"Resistance decay in individuals after antibiotic exposure in primary care: a systematic review and meta-analysis","volume":"16","author":"Bakhit","year":"2018","journal-title":"BMC Med"},{"key":"key2024110213133500_ref143-bib143","doi-asserted-by":"crossref","first-page":"194","DOI":"10.12688\/wellcomeopenres.16153.1","article-title":"Predicting the future distribution of antibiotic resistance using time series forecasting and geospatial modelling","volume":"5","author":"Jeffrey","year":"2020","journal-title":"Wellcome Open Res"},{"key":"key2024110213133500_ref144-bib144","volume-title":"Stemming the Superbug Tide: Just a Few Dollars More","author":"Organisation for Economic Co-operation and Development","year":"2019"},{"key":"key2024110213133500_ref145-bib145","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhin.2020.06.019","article-title":"The influence of hospital antimicrobial use on carbapenem-non-susceptible Enterobacterales incidence rates according to their mechanism of resistance: a time-series analysis","volume":"105","author":"Ortiz-Brizuela","year":"2020","journal-title":"J Hosp Infect"},{"key":"key2024110213133500_ref146-bib146","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijantimicag.2015.03.005","article-title":"Forecasting carbapenem resistance from antimicrobial consumption surveillance: lessons learnt from an OXA-48-producing Klebsiella pneumoniae outbreak in a west London renal unit","volume":"46","author":"Gharbi","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"key2024110213133500_ref147-bib147","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1023\/B:EJEP.0000027348.92979.94","article-title":"Generalized additive model demonstrates fluoroquinolone use\/resistance relationships for Staphylococcus aureus","volume":"19","author":"Berger","year":"2004","journal-title":"Eur J Epidemiol"},{"key":"key2024110213133500_ref148-bib148","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1093\/jac\/dkx248","article-title":"National disparities in the relationship between antimicrobial resistance and antimicrobial consumption in Europe: an observational study in 29 countries","volume":"72","author":"McDonnell","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key2024110213133500_ref149-bib149","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/jac\/dky031","article-title":"Association between use of different antibiotics and trimethoprim resistance: going beyond the obvious crude association","volume":"73","author":"Pouwels","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"key2024110213133500_ref150-bib150","doi-asserted-by":"crossref","first-page":"e0219190","DOI":"10.1371\/journal.pone.0219190","article-title":"Quantifying uncertainty about future antimicrobial resistance: comparing structured expert judgment and statistical forecasting methods","volume":"14","author":"Colson","year":"2019","journal-title":"PLOS ONE"},{"key":"key2024110213133500_ref151-bib151","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10096-009-0862-x","article-title":"Modeling antibiotic resistance to project future rates: quinolone resistance in Escherichia coli","volume":"29","author":"Durham","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key2024110213133500_ref152-bib152","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(05)17907-0","article-title":"Outpatient antibiotic use in Europe and association with resistance: a cross-national database study","volume":"365","author":"Goossens","year":"2005","journal-title":"Lancet"},{"key":"key2024110213133500_ref153-bib153","first-page":"953","article-title":"Improving feedback of surveillance data on antimicrobial consumption, resistance and stewardship in England: putting the data at your fingertips","volume":"72","author":"Johnson","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key2024110213133500_ref154-bib154","volume-title":"European Surveillance of Antimicrobial Consumption Network (ESAC-Net)","author":"European Centre for Disease Prevention and Control","year":"2021"},{"key":"key2024110213133500_ref155-bib155","volume-title":"European Antimicrobial Resistance Surveillance Network (EARS-Net)","author":"European Centre for Disease Prevention and Control","year":"2021"},{"key":"key2024110213133500_ref156-bib156","volume-title":"Antimicrobial resistance in the EU\/EEA (EARS-Net) \u2013 Annual Epidemiological Report for 2019","author":"European Centre for Disease Prevention and Control","year":"2020"},{"key":"key2024110213133500_ref157-bib157","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13756-020-00822-6","article-title":"A one health framework to estimate the cost of antimicrobial resistance","volume":"9","author":"Morel","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"key":"key2024110213133500_ref158-bib158","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S1473-3099(18)30296-2","article-title":"Quantifying drivers of antibiotic resistance in humans: a systematic review","volume":"18","author":"Chatterjee","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"key2024110213133500_ref159-bib159","doi-asserted-by":"crossref","first-page":"ofab070","DOI":"10.1093\/ofid\/ofab070","article-title":"The effect of antibiotic restriction programs on prevalence of antimicrobial resistance: a systematic review and meta-analysis","volume":"8","author":"Schuts","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"key2024110213133500_ref160-bib160","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0140-6736(15)00473-0","article-title":"Understanding the mechanisms and drivers of antimicrobial resistance","volume":"387","author":"Holmes","year":"2016","journal-title":"Lancet"},{"key":"key2024110213133500_ref161-bib161","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S0140-6736(00)04519-0","article-title":"Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction","volume":"357","author":"Enne","year":"2001","journal-title":"Lancet"},{"key":"key2024110213133500_ref162-bib162","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/bmj.324.7328.28","article-title":"Effect of betalactam antibiotic use in children on pneumococcal resistance to penicillin: prospective cohort study","volume":"324","author":"Nasrin","year":"2002","journal-title":"BMJ"},{"key":"key2024110213133500_ref163-bib163","volume-title":"Bed Availability and Occupancy Data \u2013 Overnight","author":"NHS England"},{"key":"key2024110213133500_ref164-bib164","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"key2024110213133500_ref165-bib165","volume-title":"Antimicrobial-Resistant Treatment Guidance: Gram-Negative Bacterial Infections","author":"Infectious Diseases Society of America","year":"2022"},{"key":"key2024110213133500_ref166-bib166","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S1473-3099(20)30791-X","article-title":"Personalised randomised controlled trial designs-a new paradigm to define optimal treatments for carbapenem-resistant infections","volume":"21","author":"Walker","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"key2024110213133500_ref167-bib167","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/hir.12187","article-title":"The MEDLINE UK filter: development and validation of a geographic search filter to retrieve research about the UK from OVID MEDLINE","volume":"34","author":"Ayiku","year":"2017","journal-title":"Health Info Libr J"},{"key":"key2024110213133500_ref168-bib168","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/hir.12252","article-title":"The EMBASE UK filter: validation of a geographic search filter to retrieve research about the UK from OVID EMBASE","volume":"36","author":"Ayiku","year":"2019","journal-title":"Health Info Libr J"},{"key":"key2024110213133500_ref169-bib169","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19820","article-title":"Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreath","volume":"19","author":"Harnan","year":"2015","journal-title":"Health Technol Assess"},{"key":"key2024110213133500_ref170-bib170","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/bmj.38336.804167.47","article-title":"Optimal search strategies for retrieving systematic reviews from MEDLINE: analytical survey","volume":"330","author":"Montori","year":"2005","journal-title":"BMJ"},{"key":"key2024110213133500_ref172-bib172","first-page":"MR000041","article-title":"Search strategies to identify observational studies in MEDLINE and EMBASE","volume":"3","author":"Li","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"key2024110213133500_ref173-bib173","doi-asserted-by":"crossref","first-page":"106184","DOI":"10.1016\/j.ijantimicag.2020.106184","article-title":"A systematic review on the impact of appropriate versus inappropriate initial antibiotic therapy on the outcomes of patients with severe bacterial infections","volume":"56","author":"Bassetti","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"key2024110213133500_ref174-bib174","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1017\/S0266462317000897","article-title":"Performance of Ovid MEDLINE search filters to identify health state utility studies","volume":"33","author":"Arber","year":"2017","journal-title":"Int J Technol Assess Health Care"},{"key":"key2024110213133500_ref175-bib175","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.chest.2020.03.087","article-title":"A systematic review of the effect of delayed appropriate antibiotic treatment on the outcomes of patients with severe bacterial infections","volume":"158","author":"Zasowski","year":"2020","journal-title":"Chest"},{"key":"key2024110213133500_ref176-bib176","doi-asserted-by":"crossref","first-page":"322.e7","DOI":"10.1016\/j.jcrc.2011.09.004","article-title":"The adequacy of timely empiric antibiotic therapy for ventilator-associated pneumonia: an important determinant of outcome","volume":"27","author":"Muscedere","year":"2012","journal-title":"J Crit Care"},{"key":"key2024110213133500_ref177-bib177","doi-asserted-by":"crossref","first-page":"448","DOI":"10.5507\/bp.2016.014","article-title":"Epidemiology of hospital-acquired pneumonia: results of a Central European multicenter, prospective, observational study compared with data from the European region","volume":"160","author":"Herkel","year":"2016","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"key2024110213133500_ref178-bib178","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1378\/chest.13-1018","article-title":"Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible Gram-negative bacteria","volume":"144","author":"Tumbarello","year":"2013","journal-title":"Chest"},{"key":"key2024110213133500_ref179-bib179","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10096-012-1758-8","article-title":"Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality","volume":"32","author":"Pena","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key2024110213133500_ref180-bib180","doi-asserted-by":"crossref","first-page":"e97575","DOI":"10.1371\/journal.pone.0097575","article-title":"Timing of antimicrobial therapy after identification of ventilator-associated condition is not associated with mortality in patients with ventilator-associated pneumonia: a cohort study","volume":"9","author":"Amaral","year":"2014","journal-title":"PLOS ONE"},{"key":"key2024110213133500_ref181-bib181","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/phar.2476","article-title":"Cefiderocol: a novel siderophore cephalosporin against multidrug-resistant Gram-negative pathogens","volume":"40","author":"Abdul-Mutakabbir","year":"2020","journal-title":"Pharmacotherapy"},{"key":"key2024110213133500_ref182-bib182","volume-title":"Forecasting: Principles and Practice","author":"Hyndman","year":"2018"},{"key":"key2024110213133500_ref183-bib183","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v082.i05","article-title":"An R package for analysis of count time series following generalized linear models","volume":"82","author":"Liboschik","year":"2017","journal-title":"J Statist Software"},{"key":"key2024110213133500_ref184-bib184","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S1473-3099(21)00069-4","article-title":"Effect of antibiotic stewardship interventions in primary care on antimicrobial resistance of Escherichia coli bacteraemia in England (2013\u201318): a quasi-experimental, ecological, data linkage study","volume":"21","author":"Aliabadi","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"key2024110213133500_ref185-bib185","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1177\/0272989X19873661","article-title":"Generalized linear models for flexible parametric modeling of the hazard function","volume":"39","author":"Kearns","year":"2019","journal-title":"Med Decis Making"},{"key":"key2024110213133500_ref186-bib186","volume-title":"AMR Local Indicators","year":"2021"},{"key":"key2024110213133500_ref187-bib187","volume-title":"Escherichia coli (E. coli): Guidance, Data and Analysis","author":"UK Health Security Agency","year":"2017"},{"key":"key2024110213133500_ref188-bib188","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S1473-3099(17)30724-7","article-title":"Classifying antibiotics in the WHO Essential Medicines List for optimal use\u2014be AWaRe","volume":"18","author":"Sharland","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"key2024110213133500_ref190-bib190","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003543.pub3","article-title":"Interventions to improve antibiotic prescribing practices for hospital inpatients","volume":"2","author":"Davey","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"key2024110213133500_ref191-bib191","first-page":"e40","article-title":"A process evaluation of the UK-wide Antibiotic Guardian campaign: developing engagement on antimicrobial resistance","volume":"39","author":"Bhattacharya","year":"2017","journal-title":"J Pub Health"},{"key":"key2024110213133500_ref192-bib192","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ijforecast.2009.07.001","article-title":"Damped trend exponential smoothing: a modelling viewpoint","volume":"26","author":"McKenzie","year":"2010","journal-title":"Int J Forecast"},{"key":"key2024110213133500_ref193-bib193","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/aje\/kwt017","article-title":"A modeling framework for the evolution and spread of antibiotic resistance: literature review and model categorization","volume":"178","author":"Spicknall","year":"2013","journal-title":"Am J Epidemiol"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2046506","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/YAPL9347\/YAPL9347.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2046506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T07:53:17Z","timestamp":1730533997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/YAPL9347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":179,"alternative-id":["10.3310\/YAPL9347"],"URL":"https:\/\/doi.org\/10.3310\/yapl9347","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"01-2019","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"07-2022","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"10-2023","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}